Arca
Skip to content
Tools
Tools

Irritable bowel syndrome

Drug research and approvals for irritable bowel syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 111 studies of irritable bowel syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 111
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 111 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 8

Phase 3 12 of 21

Phase 2 12 of 40

Phase 1 or earlier 10

How its trials ended

982 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 202 whose ending is known, 57% met their primary endpoint, 6% missed it and 37% stopped early.

  • Completed, result not reported45046%
  • Ongoing18419%
  • Status unknown14615%
  • Met its primary endpoint11512%
  • Stopped: other or unclear404%
  • Stopped: enrollment or feasibility212%
  • Missed its primary endpoint121%
  • Stopped: lack of efficacy51%
  • Stopped: sponsor or business decision51%
  • Stopped: safety2<1%
  • Stopped: funding2<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Apr 17, 2026A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of brenipatide in the treatment of adult participants with…Brenipatide (LY3537031)Eli LillyOngoing
Mar 20, 2026A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of brenipatide in the treatment of adult participants with…Brenipatide (LY3537031)Eli LillyOngoing
Apr 10, 2024A phase 2, multicenter, randomized, placebo-controlled, double-blind induction study to evaluate the efficacy and safety of oral TAK-279 in subjects with…Zasocitinib (TAK-279, NDI-034858)Takeda Pharmaceuticals USAOngoing
Aug 27, 2021Understanding the neurocognitive effects of fecal microbiota transplantation in major depressive disorder patients with and without irritable bowel syndromeIntestinal microbes recovered from filteration, suspension and ultrafiltration…Governors of The University of CalgaryPending
Mar 5, 2020A phase 3, open-label, long-term safety study of oral linaclotide administered to pediatric participants with functional constipation (FC) or irritable bowel…Linaclotide (constella)AbbVieOngoing
Dec 19, 2017A phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the safety and efficacy of eluxadoline in pediatric…EluxadolineAbbVieClosed
Feb 5, 2015Manipulating the microbiome in inflammatory bowel disease (IBD) by antibiotics: a multicentre randomized controlled trial.Vancomycin/ Amoxicillin/ Metronidazole/ DoxycyclineThe Hospital for Sick ChildrenClosed

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Nov 26, 2012ConstellaLinaclotideAbbVie Deutschland GmbH & Co. KGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.